T Cell

The FDA has cleared an investigational new drug application allowing a novel bispecific T-cell engager to begin a phase 1 trial in patients with active, moderate-to-severe systemic lupus erythematosus, according to a press release.

The first published results of a phase 3 allogeneic T-cell therapy showed a better than 50% response rate in patients with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease.

Patients with multiple diseases that share immunologic pathways may benefit from therapies that target those shared pathways, but additional studies are needed in this area, according to a presenter at the 2023 AWIR annual conference.

In this video, Eunice Wang, MD, discussed an abstract relating to new chimeric antigen receptor T-cell therapies treating acute lymphocytic leukemia, presented at ASCO Annual Meeting.

SCOTTSDALE, Ariz. — Several new drugs and promising therapies, including chimeric antigen receptor T-cell therapy, have ushered in a “lupus renaissance,” said a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

Patients who received chimeric antigen receptor T cells for relapsed or refractory diffuse large B-cell lymphoma feared disease progression less than those who received standard regimens, results of a cross-sectional study showed.

A blood test may predict which patients are predisposed to developing treatment-related neurotoxicity after chimeric antigen receptor T-cell therapy infusion, according to researchers.

NEW ORLEANS — Making chimeric antigen receptor T cells quickly is going to become a reality, according to Nikhil C. Munshi, MD, who discusses presentations from the ASH Annual Meeting and Exposition in this video perspective.